NCT00676806TerminatedPhase 2
A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Tufts Medical Center
- Enrollment
- 7
- Locations
- 1
- Primary Endpoint
- Number of Participants With Neutrophil Engraftment
Study Overview
Brief Summary
This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.
Detailed Description
Allogeneic stem cell transplantation (SCT) following myeloablative and non-myeloablative conditioning therapy has proven curative treatment for a number of inherited and acquired hematologic disorders. The success of allogeneic transplantation is largely determined by compatibility between donor and recipient, which predicts the risk of fatal graft-versus-host disease (GVHD). Unfortunately, less than one third of patients needing an allogeneic transplant have an available compatible donor in their family. Registries have been established to match patients with compatible volunteer (unrelated) donors, but many patients, and in particular minority patients, still lack stem cell donors.
Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells, which is readily available from the placenta following childbirth. Blood banks have been established in the United States and abroad to collect, process and store UCB for use in allogeneic transplantation. To date, more than 2000 UCB transplants have been performed in adults and children around the world.
Rationale for use of Umbilical Cord Blood in Transplantation
UCB has a number of proven and theoretical advantages as an alternative source of hematopoietic stem cells for transplantation:
- Placental or umbilical cord blood is an abundantly available source of stem cells, which is currently discarded and can be harvested at no risk to the mother or infant.
- Important infectious agents, particularly CMV, are much less common in the newborn than adults, and are less likely to contaminate UCB collections.
- UCB collections, typed, cryopreserved and banked, are available on demand, eliminating delays and uncertainties that now complicate marrow collection from unrelated donors. At present, UCB can be delivered for infusion within days of the initiation of a search. This compares with a median of 3 months from search to delivery of stem cells through the registries of volunteer adult donors.
- The intensity of graft-versus-host reactivity of fetal lymphocytes appears to be less than that of adult cells and consequently fetal lymphocytes are more tolerant of HLA incompatibility. Published studies have shown that transplantation of UCB matched at 4-5/6 antigens results in a comparable incidence of GVHD to transplantation of unrelated stem cells fully matched at 6/6 antigens.
- Frozen UCB can be easily shipped, stored at the treating institution, and thawed for use when needed, compared to freshly donated stem cells which have a limited shelf-life of one day or less, necessitating coordination between harvesting surgeons, transportation, and transplantation teams.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- — to 70 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients meeting eligibility criteria for unrelated allogeneic stem cell transplantation may be considered for participation on this clinical trial if and only if they meet each of the following criteria:
- •Patients must have one of the following diagnoses
- •Relapsed or refractory hematologic malignancy, or
- •High risk hematologic malignancy in first remission, or
- •Refractory acquired marrow failure state, or
- •Inherited disorder of metabolism or marrow failure state without alternative curative therapy.
- •Patients must not have a 6/6 or 5/6 HLA-matched related donor.
- •Patients must not have a HLA-A, -B and -DRB1 high resolution matched unrelated donor following registry search, or cannot (in the opinion of the treating physician) wait the median 3 months to receive a MUD unit.
- •Patients must demonstrate an ability to understand and willingness to sign the informed consent document
- •Patients considered for myeloablative conditioning must satisfy the following additional criteria:
- •Patients must be up to age 55 (inclusive)
- •Patients must have serum direct bilirubin ≤ 2.0 mg/dl and transaminases ≤ 2x institution upper limit of normal
- •Patients must have serum creatinine ≤ 2 mg/dl with creatinine clearance ≥ 60 ml/min (either calculated or measured).
- •Patients must have MUGA scan or echocardiogram normal for the institution, but not less than 45% left ventricular ejection fraction and no clinical evidence of cardiac dysfunction.
- •Patients must have an ECOG performance status of 0 or 1 (see Appendix C).
- •Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 > 50% of predicted.
- •Patients considered for reduced-intensity conditioning must satisfy the following additional criteria:
- •Patients must not be candidates for myeloablative conditioning due to any one of the following: Prior myeloablative stem cell transplantation, Age > 50, Co morbid illness
- •In opinion of treating physician, unable to comply with or withstand rigors of myeloablative conditioning
- •Patients with leukemia must have circulating and bone marrow blast counts < 5%, all other patients must have chemotherapy responsive disease
- •Patients must be between the ages of 18 and 70 (inclusive)
- •Patients must have serum direct bilirubin ≤ 2.0 mg/dL and transaminases ≤ 3x institution upper limit of normal
- •Patients must have creatinine clearance ≥ 30 ml/min (either calculated or measured).
- •Patients must have MUGA scan or echocardiogram documenting left ventricular ejection fraction of no less than 35% and no clinical evidence of cardiac dysfunction.
- •Patients must have an ECOG performance status of 0 or 1 (see Appendix C).
- •Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 ≥ 40% of predicted.
Exclusion Criteria
- •Patients are ineligible for participation on this trial if they meet any of the following criteria:
- •Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, uncontrolled hypertension or congestive heart failure are ineligible.
- •Patients with unstable angina are not eligible.
- •Pregnant or lactating women are ineligible.
- •Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.
- •Patients with uncontrolled infection are ineligible.
- •Patients who are HIV positive or have evidence of chronic viral hepatitis are ineligible.
- •Patients unable to comply with requirements for compliance with therapeutic plan and/or scheduled evaluations
Arms & Interventions
Myeloablative conditioning
Experimental
Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
Intervention: Umbilical Cord Blood After Myeloablative Conditioning (Biological)
Reduced intensity conditioning
Experimental
Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Intervention: Umbilical Cord Blood After Reduced-Intensity Conditioning (Biological)
Outcomes
Primary Outcomes
Number of Participants With Neutrophil Engraftment
Time Frame: +45 and 90 days
Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning
Secondary Outcomes
- Proportion of Subjects With Platelet Engraftment(+45, 90, and 180 days)
- Incidence of Acute GVHD(Day +100)
- Infectious Complications in UCB Recipients.(Day +100)
- Incidence of Chronic GVHD(After Day +100)
- Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation(+180 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerRecurrent Plasma Cell MyelomaRefractory Chronic Myelogenous LeukemiaRefractory Follicular LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRecurrent Lymphoplasmacytic LymphomaMyeloproliferative NeoplasmRefractory Hodgkin LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Mantle Cell LymphomaRefractory Small Lymphocytic LymphomaT-Cell Non-Hodgkin LymphomaAggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaChronic Phase Chronic Myelogenous LeukemiaChronic Myelogenous LeukemiaMixed Phenotype Acute LeukemiaLymphomaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT00723099Fred Hutchinson Cancer Center73
Completed
Phase 2
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseNon-Hodgkin LymphomaProlymphocytic LeukemiaAcute Biphenotypic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLymphoplasmacytic LymphomaMyelodysplastic SyndromeMantle Cell LymphomaRefractory AnemiaLymphoblastic LymphomaSmall Lymphocytic LymphomaBurkitt LymphomaMarginal Zone LymphomaFollicular LymphomaPlasma Cell MyelomaMyelofibrosisAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaNCT00719888Fred Hutchinson Cancer Center135
Terminated
Not Applicable
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesT-NK Cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Mantle-CellMyelodysplasiaLymphoma, Large-Cell, DiffuseHodgkin DiseaseChronic Myelogenous LeukemiaMultiple MyelomaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaNCT00514722University of California, San Francisco4
Recruiting
Not Applicable
Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DMDiabetes Mellitus, Type 1Immunologic Deficiency SyndromesNCT03835312Children's Hospital of Fudan University50
Unknown
Phase 1
UCMSC Transplantation in the Treatment of Cartilage DamageCartilage DamageDegenerative OsteoarthritisNCT02776943South China Research Center for Stem Cell and Regenerative Medicine20